RAFAEL HOLDINGS INC-CLASS B (RFL) Stock News
NYSE:RFL - New York Stock Exchange, Inc. - US75062E1064 - Common Stock - Currency: USD
RFL Latest News and Analysis
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™
Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results
Upon completion of our proposed merger with Cyclo Therapeutics the Company intends to focus its efforts on Cyclo’s lead clinical program Trappsol® Cyclo™...
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high unmet medical need
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results
Our proposed merger with Cyclo Therapeutics advances our strategy to invest in, develop and commercialize clinical stage assets which address areas of high...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CDE, SMC, COFS, RFL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, RVNC, ARC, RFL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
RFL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Rafael Holdings, Inc. Is Fair to Shareholders
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement
Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic...
RFL Stock Earnings: Rafael Holdings Reported Results for Q3 2024
Rafael Holdings just reported results for the third quarter of 2024.
RFL Stock Earnings: Rafael Holdings Reported Results for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rafael Holdings (NYSE:RFL) just reported results for the third quarter of 2024....
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential
Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results
Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive...
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments ...
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
Rafael Holdings just reported results for the first quarter of 2024.
RFL Stock Earnings: Rafael Holdings Reported Results for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Rafael Holdings (NYSE:RFL) just reported results for the first quarter of 2024....
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments
Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments...
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities...
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase our investment by $5 million
Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update
Since the end of the third quarter, we made an initial $2.1 million investment in Cyclo Therapeutics, Inc. (Nasdaq: CYTH) and have an agreement to increase...
Cyclo Therapeutics and Rafael enter agreement for $5M funding (NASDAQ:CYTH)
Clinical stage biotechnology company, Cyclo Therapeutics (CYTH) enters into an agreement with Rafael (RFL) to purchase 4M shares and warrants for an aggregate purchase price of $5M